Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for delirium prevention in high-risk Japanese patients
NCT04571944Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Suvorexant with Placebo (2 arms). Primary endpoints: Percentage of Participants With Delirium as Assessed by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria at 8 days, Number of Participants Who Experienced One or More Adverse Events (AEs) at 21 days and 1 more. Started Oct 2020; status: completed.
02
Drugs
suvorexant
03
Conditions
delirium
Beyond the preview
Go deeper on NCT04571944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571944.